Published on October 28, 2009 at 7:13 AM
The Board issued a Notice of Hearing on March 16, 2009, pertaining to allegations of Board Staff that Neulasta had been, and was being, sold by Amgen Canada Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On October 13, 2009, the Hearing Panel received a Joint Submission by Amgen and Board Staff along with a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Neulasta proceedings.
Amgen will reduce the price at which it sells Neulasta to the 2009 maximum price, and will make a payment to the Government of Canada in the amount of $6,730,120.32 to offset any revenues above the maximum prices from the date of introduction of Neulasta to June 30, 2009. Amgen will also offset revenues greater than the 2009 maximum price it received from July 1, 2009 to December 31, 2009.
Amgen will ensure that the price of Neulasta remains within the Board's Guidelines for the period it remains under the Board's jurisdiction.
By Order of the Board, the proceeding into the price of Neulasta is concluded.
SOURCE Amgen Canada Inc.